ClinicalTrials.gg
CompletedNCT00184652Updated Jan 24, 2017

Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

A Phase 2 interventional study of somatropin in Chronic Kidney Disease and End-Stage Renal Disease, sponsored by Novo Nordisk A/S. Completed at 26 sites in 9 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-01-24.

Primary conditionKidney Failure, ChronicRegistry: Renal Insufficiency, ChronicReclassifiedWhy we changed it
Registry
Renal Insufficiency, Chronic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. The study's listed conditions name Kidney Failure, Chronic, a narrower term within Renal Insufficiency, Chronic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 103 studies in Kidney Failure, Chronic with a site in United Kingdom — 15 open to participants now, 23 under way, 5 of them phase 3. Kidney Failure, Chronic · United Kingdom.

Enrollment
21st of 77
140 · median 80
Started
2003
the only one that year
Phase 2
19 of 103
3 open now
Registered
5th of 103
by date

Among the 103 studies in Kidney Failure, Chronic with a site in United Kingdom, this one is the 21st largest by enrollment of the 77 interventional ones that give a count, is the only one that started in 2003, is one of 19 in phase 2, and was the 5th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

15 of the 103 studies in Kidney Failure, Chronic with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Kidney Failure, Chronic with a site in United Kingdom, or all of them as a file.
02

Study summary

This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney disease are treated with growth hormone to assess effect on nutritional status.

03

Conditions studied

  • Chronic Kidney Disease
  • End-Stage Renal Disease

Browse trials for

04

In context

Kidney Failure, Chronic Reclassified

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

This study's enrollment of 140 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ESRD patients

Exclusion criteria

Exclusion Criteria:

  • Diabetes Mellitus
  • Severe and Malignant diseases
  • Patients in Intensive Care Units
06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
140 participants (actual)

Interventions

07

What researchers measure

Primary outcomes

  1. Change in surrogate markers of nutrition

    Time frame: After 6 months treatment

Secondary outcomes

  1. Quality of Life

  2. Other markers of nutrition

08

Study locations

26 sites
  • Novo Nordisk Investigational Site
    København Ø, 2100, Denmark
  • Novo Nordisk Investigational Site
    Odense, 5000, Denmark
  • Novo Nordisk Investigational Site
    Århus N, 8200, Denmark
  • Novo Nordisk Investigational Site
    Berlin, 13353, Germany
  • Novo Nordisk Investigational Site
    Heidelberg, 69115, Germany
  • Novo Nordisk Investigational Site
    Hong Kong, Hong Kong
  • Novo Nordisk Investigational Site
    Holon, 58100, Israel
  • Novo Nordisk Investigational Site
    Kfar Saba, 44281, Israel
  • Novo Nordisk Investigational Site
    Petach Tikva, 49100, Israel
  • Novo Nordisk Investigational Site
    Ramat Gan, 52621, Israel
  • Novo Nordisk Investigational Site
    Tel-Aviv, 64239, Israel
  • Novo Nordisk Investigational Site
    Tzriffin, 70300, Israel
  • Novo Nordisk Investigational Site
    Krakow, 31-501, Poland
  • Novo Nordisk Investigational Site
    Lublin, 20 - 094, Poland
  • Novo Nordisk Investigational Site
    Wolomin, 05-200, Poland
  • Novo Nordisk Investigational Site
    Singapore, 119074, Singapore
  • Novo Nordisk Investigational Site
    Göteborg, 417 17, Sweden
  • Novo Nordisk Investigational Site
    Bern, 3010, Switzerland
  • Novo Nordisk Investigational Site
    Birmingham, B9 5SS, United Kingdom
  • Novo Nordisk Investigational Site
    Coventry, CV2 2DX, United Kingdom
  • Novo Nordisk Investigational Site
    Glasgow, G11 6NT, United Kingdom
  • Novo Nordisk Investigational Site
    Liverpool, L69 3GA, United Kingdom
  • Novo Nordisk Investigational Site
    Manchester, M13 0HZ, United Kingdom
  • Novo Nordisk Investigational Site
    Newcastle, NE7 7DN, United Kingdom
  • Novo Nordisk Investigational Site
    Sheffield, S5 7AU, United Kingdom
  • Novo Nordisk Investigational Site
    Swansea, SA6 6NL, United Kingdom
09

References and documents

Publications

  • Feldt-Rasmussen B, Lange M, Sulowicz W, Gafter U, Lai KN, Wiedemann J, Christiansen JS, El Nahas M; APCD Study Group. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol. 2007 Jul;18(7):2161-71. doi: 10.1681/ASN.2006111207. Epub 2007 Jun 6. PubMed 17554147 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 16, 2005
Start
Apr 2003
Primary completionActual
Sep 2005
CompletionActual
Sep 2005
Last update
Jan 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00184652
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 16, 2005
Start date
Apr 2003
Primary completion
Sep 2005
Completion
Sep 2005
Last update
Jan 24, 2017

Study contacts

Global Clinical Registry (GCR 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion